Mar 19 |
Chief Legal Officer Edmondson Frazor Titus III Sells 10,000 Shares of Zai Lab Ltd (ZLAB)
|
Mar 13 |
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
|
Mar 6 |
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
|
Mar 6 |
Zai Lab Announces Participation in March Investor Conference
|
Feb 29 |
Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript
|
Feb 28 |
Zai Lab Limited (ZLAB) Q4 2023 Earnings Call Transcript
|
Feb 27 |
Recap: Zai Lab Q4 Earnings
|
Feb 27 |
Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results
|
Feb 27 |
Zai Lab GAAP EPadS of -$3.46 beats by $0.01, revenue of $266.72M misses by $2.06M
|
Feb 27 |
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
|